Metabolic syndrome. Metabolic syndrome
Conditions
Interventions
Intervention 1: Intervention group: Intervention group given daily omega-3 supplement in the form of 1000 mg gel made by Zahravi Pharmaceutical Company of Tabriz. Intervention 2: Control group: Omega-
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Interested in attending the study who have completed and signed the informed consent form. Metabolic syndrome according to existing criteria, including: There are 3 of the following: Waist circumference = 80 cm for women and Waist circumference = 94 cm for men, fasting blood glucose = 100 mg / dl , Systolic blood pressure = 130 and diastolic blood pressure above = 85 , mm Hg, HDL less than 50 mg / dL for women and less than 40 mg / dL for men and triglycerides; 150 mg / dL and drug administration for triglycerides Blood glyceride, cholesterol and LDL (including statins, etc.). With ischemic heart disease.
Exclusion criteria
Exclusion criteria: Mental, emotional, cognitive, or any disorders that may prevent a person from participating in this study. People who have certain dietary restrictions and follow a specific diet. autoimmune diseases (corticosteroids), cancer alcohol consumption Pregnancy Breastfeeding Infectious Diseases Chronic Kidney Disease Liver disease Food intolerance and sensitivity to fish Drug abuse Anticoagulants such as warfarin Changes in the level of physical activity during the study People taking Omega-3 supplements Consume more than one serving of fish per week Omega-3 sensitivity cases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Triglyceride. Timepoint: Blood triglyceride levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum triglyceride concentration measurement by enzymatic method with BT1500.;High-density lipoprotein. Timepoint: Blood High-density lipoprotein levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum high-density lipoprotein concentration measurement by enzymatic method with BT1500.;Low-density lipoprotein. Timepoint: Blood Low-density lipoprotein levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum low-density lipoprotein concentration measurement by enzymatic method with BT1500.;Fasting blood sugar. Timepoint: Blood Fasting blood sugar levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum fasting blood sugar concentration measurement by enzymatic method with BT1500.;Total cholesterol. Timepoint: Blood Total cholesterol levels at baseline (before intervention) and at the end of the study at week 12. Method of measurement: Serum total cholesterol concentration measurement by enzymatic method with BT1500.;Waist circumference. Timepoint: Waist measurement at baseline (before intervention) and at weeks 4, 8 and end of study at week 12. Method of measurement: Using meters and in centimeters. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: Weight measurement at baseline (before intervention) and at 4, 8 and 12 weeks. Method of measurement: The weight of a person with minimal clothing and no shoes is measured to the nearest 100 grams.;Body Mass Index. Timepoint: Body Mass Index measurement at baseline (before intervention) and at 4, 8 and 12 weeks. Method of measurement: Using the values of height and weight and by the formula of weight divided by the square of height in meters.;Physical activity. Timepoint: Physical activity measurement at baseline (before intervention) and at 4, 8 and 12 weeks. Method of measurement: Measurement of physical activity at three levels of light, moderate and vigorous using the International Physical Activity Questionnaire.;Systolic blood pressure. Timepoint: Systolic blood pressure measurement at baseline (before intervention) and at 4, 8 and 12 weeks. Method of measurement: Using a calibrated digital barometer.;Diastolic blood pressure. Timepoint: Diastolic blood pressure measurement at baseline (before intervention) and at 4, 8 and 12 weeks. Method of measurement: Using a calibrated digital barometer.;Feed Frequency Questionnaire. Timepoint: Feed Frequency Questionnaire at the beginning of the study (before the intervention) and at the end of the 12 week study. Method of measurement: Using a food frequency questionnaire.;Height. Timepoint: Measurement of individuals height at baseline (before intervention). Method of measurement: Using the height gauge. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAsma Zamanian
Oroumia University of Medical Sciences
Outcome results
None listed